Deals
Vivo Capital, Bain Back Chinese Biotech Firm in $200 Million Fundraising
- Primavera also joins Vivo Capital-led series A round
- Funding to support combination with Pearl Biotechnology
This article is for subscribers only.
Chinese biotechnology firm Avistone Pharmaceuticals has raised over $200 million in a series A round led by Vivo Capital in one of the largest such deals for the sector.
Private equity firms Bain Capital and Primavera Capital also participated in the fundraising, Beijing-based Avistone said in a statement.